Abstract
Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3006-3017 |
| Number of pages | 12 |
| Journal | Journal of the American College of Cardiology |
| Volume | 73 |
| Issue number | 23 |
| DOIs | |
| State | Published - Jun 18 2019 |
Fingerprint
Keywords
- blood pressure
- cardiovascular disease
- hypertension
- renal denervation
- sympathetic nervous system
Cite this
Renal Denervation Update From the International Sympathetic Nervous System Summit : JACC State-of-the-Art Review. / Kiuchi, Márcio G.; Esler, Murray D.; Fink, Gregory D.; Osborn Jr, John W; Banek, Christopher T; Böhm, Michael; Denton, Kate M.; DiBona, Gerald F.; Everett, Thomas H.; Grassi, Guido; Katholi, Richard E.; Knuepfer, Mark M.; Kopp, Ulla C.; Lefer, David J.; Lohmeier, Thomas E.; May, Clive N.; Mahfoud, Felix; Paton, Julian F.R.; Schmieder, Roland E.; Pellegrino, Peter R.; Sharabi, Yehonatan; Schlaich, Markus P.
In: Journal of the American College of Cardiology, Vol. 73, No. 23, 18.06.2019, p. 3006-3017.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Renal Denervation Update From the International Sympathetic Nervous System Summit
T2 - JACC State-of-the-Art Review
AU - Kiuchi, Márcio G.
AU - Esler, Murray D.
AU - Fink, Gregory D.
AU - Osborn Jr, John W
AU - Banek, Christopher T
AU - Böhm, Michael
AU - Denton, Kate M.
AU - DiBona, Gerald F.
AU - Everett, Thomas H.
AU - Grassi, Guido
AU - Katholi, Richard E.
AU - Knuepfer, Mark M.
AU - Kopp, Ulla C.
AU - Lefer, David J.
AU - Lohmeier, Thomas E.
AU - May, Clive N.
AU - Mahfoud, Felix
AU - Paton, Julian F.R.
AU - Schmieder, Roland E.
AU - Pellegrino, Peter R.
AU - Sharabi, Yehonatan
AU - Schlaich, Markus P.
PY - 2019/6/18
Y1 - 2019/6/18
N2 - Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.
AB - Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.
KW - blood pressure
KW - cardiovascular disease
KW - hypertension
KW - renal denervation
KW - sympathetic nervous system
UR - http://www.scopus.com/inward/record.url?scp=85066481995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066481995&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2019.04.015
DO - 10.1016/j.jacc.2019.04.015
M3 - Review article
VL - 73
SP - 3006
EP - 3017
JO - Journal of the American College of Cardiology.
JF - Journal of the American College of Cardiology.
SN - 0735-1097
IS - 23
ER -